证券代码：000739 证券简称：普洛药业 公告编号：2025-36 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 6 月 10 日，普洛药业股份有限公司（以下简称"公司"）与中 国银行股份有限公司东阳支行（以下简称"中国银行"）签订《保证合同》（合 同编号：横店 2025 人保字 095 号），同意为公司全资子公司浙江普洛家园药业 有限公司（以下简称"家园药业"）与中国银行签署的《商业汇票承兑协议》（合 同编号：横店 2025 人承字 095 号）中的 10,000 万元银行承兑汇票提供连带责任 保证，担保期限 6 个月。 6、2025 年 6 月 25 日，公司与中国银行签订《保证合同》（合同编号：横 店 2025 人保字 112 号），同意为公司控股子公司浙江普洛康裕制药有限公司（以 下简称"康裕制药"）与中国银行签署的《商业汇票承兑协议》（合同编号：横 店 2025 人承字 112 号）中的 2,859 万元流动资金借款提供连带责任保证，担保 期限 6 个月。 7 ...

Investment Rating - The report maintains a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Bioscience, Hualing Pharmaceutical-B, and others [2]. Core Insights - The report emphasizes the broad market for lipid-lowering treatments, particularly focusing on the competitive landscape of PCSK9-targeted drugs, with approximately 500 million adults in China suffering from dyslipidemia, including 120 million with high cholesterol [3][15]. - The pharmaceutical sector saw a 1.60% increase this week, underperforming the CSI 300 index by 0.35 percentage points, with sub-sectors like medical infrastructure and life sciences performing better than generics and innovative drugs [4][31]. Summary by Sections 1. Industry Perspective and Investment Recommendations - The lipid-lowering market is vast, with intense competition in PCSK9-targeted drugs [15]. - Investment strategies should focus on innovative drugs, particularly in the context of increased liquidity and risk appetite in the market [4][31]. 2. Pharmaceutical Sector Performance - The pharmaceutical sector's performance was mixed, with medical infrastructure and life sciences leading, while generics and innovative drugs lagged [4][37]. - The overall P/E ratio for the pharmaceutical industry is 27.69, with a premium of 35.26% compared to the broader A-share market [37]. 3. Company Dynamics - Notable company announcements include Baiyoutai's licensing agreement for BAT2406 in Latin America and Yifan Pharmaceutical's approval for clinical trials of a growth hormone injection [38][40]. - Companies like WuXi AppTec and Lijun Group have made significant moves, including share buybacks and new product approvals [39][41]. 4. Industry Trends - The report highlights the upcoming patent expirations for major small molecule drugs, which could lead to increased demand for raw materials [5][32]. - The report also notes the expected recovery in overseas demand, which may improve the performance of CXO companies [34]. 5. Research and Development Focus - The report discusses the clinical progress of various PCSK9-targeted therapies, including monoclonal antibodies and gene editing approaches, indicating a strong pipeline in this area [3][23][25]. - The competitive landscape for PCSK9 drugs in China is characterized by pricing and adherence challenges, with several products already on the market [27].

Group 1 - The central government has clarified the standards for identifying violations of public officials' dining regulations, emphasizing the importance of understanding the relationships of participants, the nature of the dining location, and the source of funds [5][6] - The National Development and Reform Commission has included 30 national logistics hubs, including Wuhan, in its construction list, aiming to enhance industrial integration, international logistics channels, and operational efficiency [7] - Shanghai Customs has seized 6,960 counterfeit "POP MART" toys, which were found to infringe on trademark rights, and the case is under further investigation [8] Group 2 - The former director of the National Administration of Traditional Chinese Medicine, Yu Wenming, is under investigation for serious job-related violations [9] - Platinum prices have surged over 36% this year, surpassing gold's increase, with China becoming the largest retail platinum investment market, reflecting a significant rise in demand [9] - The Indian airline has announced a 5% reduction in narrow-body aircraft flights and the suspension of certain international and domestic routes to maintain operational stability following a recent aircraft accident [17]

Core Viewpoint - The company has completed the cancellation of repurchased shares, reducing its total share capital from 1,169,323,576 shares to 1,158,443,576 shares, which is expected to enhance earnings per share and improve shareholder returns [1][2][3] Summary by Sections 1. Approval and Implementation of Share Repurchase - The company approved a share repurchase plan on March 27, 2024, allowing for the repurchase of shares at a price not exceeding RMB 20 per share, with a total repurchase fund of at least RMB 153 million [1][2] - The actual repurchase involved 10,880,000 shares, accounting for 0.93% of the total share capital, with a total transaction amount of approximately RMB 153 million [1][2] 2. Cancellation of Repurchased Shares - The cancellation of the repurchased shares was confirmed by the China Securities Depository and Clearing Corporation on June 19, 2025, in compliance with relevant laws and regulations [2][3] - The number of shares canceled was 10,880,000, which represented 0.93% of the total share capital before cancellation [2] 3. Changes in Shareholding Structure - Following the cancellation, the total number of shares decreased to 1,158,443,576, with the structure remaining compliant with listing requirements [2][3] - The proportion of unrestricted circulating shares slightly decreased from 99.9628% to 99.9624% after the cancellation [2] 4. Impact of Share Cancellation - The cancellation is expected to enhance the company's earnings per share and improve returns for shareholders without significantly affecting the company's financial status or future development [3] - The cancellation will not harm the interests of shareholders, particularly minority shareholders, and will not lead to changes in the controlling shareholder or actual controller [3] 5. Follow-up Arrangements - The company will proceed with necessary changes in business registration and articles of association as per legal requirements following the completion of the share cancellation [3]

证券代码：000739 证券简称：普洛药业 公告编号：2025-34 普洛药业股份有限公司 关于回购股份注销完成暨股份变动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次注销的回购股份数量为 10,880,000 股，占注销前公司总股本的 0.93%。 本次注销完成后，公司总股本将由 1,169,323,576 股变更为 1,158,443,576 股。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次回购股份 注销事宜已于 2025 年 6 月 19 日办理完成。 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规 定，回购股份注销完成后，公司应当及时披露，并及时办理变更登记手续。现将公 司回购股份注销完成暨股份变动的具体情况公告如下： 一、本次回购股份的批准及实施情况 关法律法规和公司回购股份方案的有关要求。 公司于 2025 年 3 月 7 日召开第九届董事会第十一次会议，并于 2025 年 4 月 17 日召开 2024 年年度股东大会，审议通过了《关于注销回购股份并减少注册资本的议 案》 ...

Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

Group 1: CD73 and Cancer Immunotherapy - CD73 is a promising target for cancer immunotherapy, acting as a rate-limiting enzyme in the production of extracellular adenosine, which has immunosuppressive effects in various diseases [1] - CD73 is overexpressed in the tumor microenvironment (TME) of several cancer types, including breast cancer, melanoma, and lung cancer, and plays a significant role in immune regulation [1] - Several products targeting CD73 are in clinical research, with leading small molecule inhibitors being Arcus's AB680 and Deqi's ATG-037, while monoclonal antibodies like AstraZeneca's Oleclumab and Tianjing's Uliledlimab have entered Phase 3 trials [1] Group 2: Pharmaceutical Sector Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs, vaccines, and medical packaging performing relatively well [1] - The investment strategy suggests focusing on the impact of market pricing power and capital changes, particularly in AI healthcare and innovative drugs [1] - The domestic dual-antibody ADCs, TYK2 inhibitors, GKA agonists, and pan-KRAS inhibitors are considered globally leading pipelines, with recommended companies including Innovent Biologics, Baiyi Tianheng, and others [1] Group 3: API Market Dynamics - From 2025 to 2030, the sales impact of expiring formulation patents is projected to be $390 billion, a 124% increase compared to the total from 2019 to 2024, indicating a significant demand for APIs [2] - In 2024, the output of APIs in large-scale industrial enterprises is expected to reach 3.583 million tons, a 4.6% year-on-year increase, with Q2 and Q3 showing substantial growth [2] - India's imports of APIs and intermediates from China are projected to reach 3.4 billion yuan in 2024, with a rapid growth in import volume, indicating a recovery in the API industry [2] Group 4: CXO Sector Insights - The Federal Reserve's dovish stance is expected to lead to increased liquidity, with predictions of rate cuts in 2025 and 2026, which may shift investment preferences towards undervalued sectors like pharmaceuticals [3] - The recovery in overseas investment and domestic innovative drug performance is anticipated to improve local financing conditions, with a projected $58.2 billion in global healthcare financing in 2024 [3] - The demand for CXO services is expected to improve as overseas orders recover, positively impacting performance in the sector [3] Group 5: Company Recommendations - Companies benefiting from domestic innovative drug support policies include clinical CROs like Sunshine Nuohe and Nuosige, while life science upstream companies like Haoyuan Pharmaceutical are expected to benefit from overseas business recovery [4] - The generics sector is poised for growth due to policy changes, with recommendations for companies with rich pipelines and high efficiency, such as Kelun Pharmaceutical and Yifan Pharmaceutical [4]

Core Viewpoint - The article discusses the current state and future trends of the active pharmaceutical ingredients (API) industry in China, highlighting the competitive landscape, market dynamics, and the impact of regulatory changes on production and supply chains [4][5][6]. Industry Chain Overview - The API industry chain includes upstream basic chemicals and agriculture, midstream API production through various methods, and downstream chemical formulation production [4][5]. - The production segment of APIs requires high technical standards and is influenced by fluctuations in raw material prices and changes in downstream market demand [5]. Supply Chain Characteristics - China's API supply chain is characterized by high regional concentration and strong scale, with major production bases in East China and parts of the Midwest [7]. - The country holds a global price influence in bulk raw materials, supporting the large-scale development of the API industry, although it faces structural issues such as environmental regulations and reliance on imports for high-end intermediates [7]. Competitive Landscape - As of 2023, there are 1,661 API manufacturers in China, with significant concentrations in Jiangsu and Zhejiang provinces [9]. - Major competitors in the domestic API market include companies like New Chemical, Tianyu Co., and Prolo Pharmaceutical, which hold substantial market shares [13][14]. Market Segmentation - The API market is segmented into bulk APIs, specialty generic APIs, and patented APIs, with each segment exhibiting different growth rates and competitive dynamics [21][22]. - The bulk API market is mature with stable demand, while specialty APIs are characterized by higher technical barriers and profit margins [21]. Market Trends - The bulk API market is projected to reach approximately 300 billion RMB in 2024, with over 60% of production destined for export [23]. - The patented API market is expected to grow rapidly, with a projected market size of 30 billion RMB by 2024, driven by increasing demand from international pharmaceutical companies [24]. Production and Export Dynamics - China's API production has been increasing, with a record output of 401,000 tons in December 2023, reflecting strong downstream demand [27]. - The export value of APIs reached 42.98 billion USD in 2024, with a year-on-year growth of 5.1%, indicating a recovery from previous declines [37][39]. Future Outlook - The API industry is transitioning from a volume-driven model to a value-driven approach, focusing on high-quality and diversified development [17]. - The competitive landscape is intensifying, with price wars becoming common as companies vie for market share, leading to a 12% decrease in average export prices in 2024 [56].

Group 1 - Kangfang Biotech's PD-1/CTLA-4 bispecific antibody KAITENI® has received approval for a new indication in the treatment of cervical cancer, marking the third indication for this drug [1] - Tianyi Medical has obtained product registration certificates for single-use continuous renal replacement therapy tubing and single-use hemodialysis tubing, both sterilized with ethylene oxide [2] - Jincheng Pharmaceutical's posaconazole enteric-coated tablets and injectable cefoperazone sodium have been approved, enhancing the company's competitiveness in the antifungal and anti-infection sectors [3] Group 2 - Prolo Pharma has received approval for the raw material drug succinate desvenlafaxine, expanding its product pipeline in the antidepressant treatment field [4] - Wantai Biological Pharmacy's first domestically produced nine-valent HPV vaccine has been approved, with approximately 1 billion yuan invested in research and development as of May 2025 [5] - Yuheng Pharmaceutical's subsidiary has signed a market promotion service agreement with Eisai (China) Pharmaceutical for the exclusive promotion of mecobalamin injection, which is used for peripheral neuropathy and vitamin B12 deficiency-related anemia [6]

Policy Developments - The National Healthcare Security Administration has revised the medical price and procurement credit evaluation system to combat commercial bribery and encourage integrity among pharmaceutical companies [2][3] - The revised system aims to increase the cost of dishonesty for companies and promote compliance, quality improvement, and effective market participation through collective procurement and national negotiations [2][3] Industry Updates - The internal whistleblower reward system for drug and medical device quality safety has been announced, incentivizing individuals who provide clear evidence of violations that lead to administrative penalties or criminal prosecution [4] - A notification has been issued to promote pain relief services during childbirth across various medical institutions, with goals set for 2025 and 2027 to ensure comprehensive service availability [5] Company News - Puluo Pharmaceutical has received approval for the listing application of Succinic Acid Desvenlafaxine, a third-generation antidepressant for treating major depressive disorder [7] - China Pharmaceutical has obtained a drug registration certificate for Sulfhydryl Clopidogrel Tablets, aimed at secondary prevention of atherosclerotic thromboembolic events in specific patient groups [8] - Shanghai Sipurei Pharmaceutical Technology has completed over 200 million RMB in angel round financing, with funds allocated for preclinical and early clinical development [11] - Kelun Pharmaceutical's subsidiary plans to raise approximately 1.943 billion HKD through a share placement to support product development and operational needs [12] - Merck KGaA has entered a strategic partnership with Zai Lab to commercialize a recombinant human thyroid-stimulating hormone in mainland China [14] - China National Pharmaceutical Group has established a technology innovation research institute with a registered capital of 1 billion RMB, focusing on various research and development activities [15] Management Changes - Tongrentang Technology announced the resignation of its chairman and general manager due to work changes, indicating potential shifts in company leadership [17]